Podcast Episodes
Back to SearchThe importance of addressing quality of life and improving symptom management in MPNs
Episode 206
Myeloproliferative neoplasms (MPNs) represent a challenging group of diseases to treat, and patients with MPNs suffer from several symptoms which neg…
3 years, 2 months ago
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team
Amyloidosis is a rare disease in which insoluble amyloid proteins are deposited in tissues or organs, resulting in organ damage. The diagnosis and tr…
3 years, 2 months ago
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team
Episode 205
Amyloidosis is a rare disease in which insoluble amyloid proteins are deposited in tissues or organs, resulting in organ damage. The diagnosis and tr…
3 years, 2 months ago
Hemophilia: the current standard of care and the value of novel gene therapies
Over the years, the hemophilia treatment landscape has transformed, with novel agents aiming to improve patient care and quality of life. Factor repl…
3 years, 3 months ago
Hemophilia: the current standard of care and the value of novel gene therapies
Episode 204
Over the years, the hemophilia treatment landscape has transformed, with novel agents aiming to improve patient care and quality of life. Factor repl…
3 years, 3 months ago
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors
Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL), with both covalent and non-…
3 years, 3 months ago
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors
Episode 203
Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL), with both covalent and non-…
3 years, 3 months ago
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients with relapsed/refr…
3 years, 3 months ago
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
Episode 202
In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients with relapsed/refr…
3 years, 3 months ago
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
The treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies including bispecific antibodies a…
3 years, 3 months ago